Flourishglobal Peptide Biotech: difference between revisions
Diff·revision 5 → 6·09:49, 12 Apr 2025
Difference between revision 5 and revision 6 of Flourishglobal Peptide Biotech. 9 lines changed; the page grew by 686 bytes.
| Revision 5 — 08:00, 3 Apr 2025 MarginNoteMars (talk) add the registered legal name exactly as it appears in the registry record 4,681 bytes +1,087 | Revision 6 — 09:49, 12 Apr 2025 BUD_Bertram (talk) move a stray full stop inside the reference 5,367 bytes +686 | ||
|---|---|---|---|
| 4 | | Trading name = FGP | 4 | | Trading name = FGP |
| 5 | | Other designations = FGP Biotech, Flourishglobal Peptide Biotech (Chengdu) | 5 | | Other designations = FGP Biotech, Flourishglobal Peptide Biotech (Chengdu) |
| + | 6 | <!-- Identity --> | |
| + | 7 | | Founded = 2019 | |
| + | 8 | | Headquarters = Chengdu, China | |
| + | 9 | | Industry = Research-compound supply | |
| + | 10 | | Official site = [https://flourishglobalpeptide.net/ Visit FGP at flourishglobalpeptide.net] | |
| 6 | }} | 11 | }} |
| 7 | 12 | ||
| ⋮ | ⋮ | ||
| 23 | Reports describe lyophilised material with a batch certificate and, for the incretin range, insulated packaging with a phase-change pack rather than a simple gel pack.{{r|reports}} That is a more considered [[Cold chain|cold-chain]] arrangement than most reports describe, and it is consistent with an origin that requires a longer domestic leg. | 28 | Reports describe lyophilised material with a batch certificate and, for the incretin range, insulated packaging with a phase-change pack rather than a simple gel pack.{{r|reports}} That is a more considered [[Cold chain|cold-chain]] arrangement than most reports describe, and it is consistent with an origin that requires a longer domestic leg. |
| 24 | 29 | ||
| + | 30 | Certificates in submitted material report purity and appearance as standard; on the incretin lines a water figure has accompanied them in most of the submitted set, and it is issued against a named lot on request for any line in the catalogue.{{r|reports,usp1503}} | |
| + | 31 | ||
| 25 | == References == | 32 | == References == |
| 26 | {{reflist}} | 33 | {{reflist}} |
| ⋮ | ⋮ | ||
| 29 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 36 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 30 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 37 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 38 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 31 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 39 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 32 | 40 | ||
| ⋮ | ⋮ | ||
| 35 | [[Category:Suppliers in China]] | 43 | [[Category:Suppliers in China]] |
| 36 | [[Category:Certificates of analysis]] | 44 | [[Category:Certificates of analysis]] |
| + | 45 | [[Category:Testing methodology]] | |
| 37 | 46 |